<?xml version='1.0' encoding='utf-8'?>
<document id="30044899"><sentence text="Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers."><entity charOffset="0-10" id="DDI-PubMed.30044899.s1.e0" text="Amenamevir" /><entity charOffset="82-91" id="DDI-PubMed.30044899.s1.e1" text="Midazolam" /><entity charOffset="93-105" id="DDI-PubMed.30044899.s1.e2" text="Cyclosporine" /><entity charOffset="111-120" id="DDI-PubMed.30044899.s1.e3" text="Ritonavir" /><pair ddi="false" e1="DDI-PubMed.30044899.s1.e0" e2="DDI-PubMed.30044899.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30044899.s1.e0" e2="DDI-PubMed.30044899.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30044899.s1.e0" e2="DDI-PubMed.30044899.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30044899.s1.e0" e2="DDI-PubMed.30044899.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30044899.s1.e1" e2="DDI-PubMed.30044899.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30044899.s1.e1" e2="DDI-PubMed.30044899.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30044899.s1.e1" e2="DDI-PubMed.30044899.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30044899.s1.e2" e2="DDI-PubMed.30044899.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30044899.s1.e2" e2="DDI-PubMed.30044899.s1.e3" /></sentence><sentence text="Amenamevir (formerly ASP2151) is a helicase-primase inhibitor being developed for the treatment of herpesvirus infection"><entity charOffset="0-10" id="DDI-PubMed.30044899.s2.e0" text="Amenamevir" /></sentence><sentence text=" Amenamevir is both a substrate and inducer of cytochrome P450 (CYP) 3A4" /><sentence text=" Three studies were done in healthy volunteers to investigate potential CYP3A pharmacokinetic interactions with the following drugs: (1) Midazolam (probe substrate for CYP3A): After 10 days' pretreatment with amenamevir 400 mg daily, geometric mean maximum concentration of drug in blood plasma (Cmax ) and area under the plasma drug concentration-time curve from time zero to infinity (AUC0-∞ ) of midazolam 7"><entity charOffset="137-146" id="DDI-PubMed.30044899.s4.e0" text="Midazolam" /></sentence><sentence text="5 mg were about 68% and 51%, respectively, of those after midazolam alone"><entity charOffset="58-67" id="DDI-PubMed.30044899.s5.e0" text="midazolam" /></sentence><sentence text=" (2) Cyclosporine (substrate and inhibitor of CYP3A): After 5 days' pretreatment with cyclosporine 100 mg twice daily, geometric mean Cmax of amenamevir after 400-mg and 1200-mg single doses was, respectively, about 66% and 69%, and AUC0-∞ about 82% and 79%, of those after amenamevir alone"><entity charOffset="5-17" id="DDI-PubMed.30044899.s6.e0" text="Cyclosporine" /><entity charOffset="86-98" id="DDI-PubMed.30044899.s6.e1" text="cyclosporine" /><entity charOffset="142-152" id="DDI-PubMed.30044899.s6.e2" text="amenamevir" /><pair ddi="false" e1="DDI-PubMed.30044899.s6.e0" e2="DDI-PubMed.30044899.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30044899.s6.e0" e2="DDI-PubMed.30044899.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30044899.s6.e0" e2="DDI-PubMed.30044899.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30044899.s6.e1" e2="DDI-PubMed.30044899.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30044899.s6.e1" e2="DDI-PubMed.30044899.s6.e2" /></sentence><sentence text=" (3) Ritonavir (inhibitor of CYP3A): When given with single doses of ritonavir 600 mg, geometric mean Cmax of amenamevir after 400-mg and 1200-mg single doses was, respectively, about 1"><entity charOffset="5-14" id="DDI-PubMed.30044899.s7.e0" text="Ritonavir" /><entity charOffset="69-78" id="DDI-PubMed.30044899.s7.e1" text="ritonavir" /><entity charOffset="110-120" id="DDI-PubMed.30044899.s7.e2" text="amenamevir" /><pair ddi="false" e1="DDI-PubMed.30044899.s7.e0" e2="DDI-PubMed.30044899.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30044899.s7.e0" e2="DDI-PubMed.30044899.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30044899.s7.e0" e2="DDI-PubMed.30044899.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30044899.s7.e1" e2="DDI-PubMed.30044899.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30044899.s7.e1" e2="DDI-PubMed.30044899.s7.e2" /></sentence><sentence text="4 and 1" /><sentence text="6 times higher, and geometric mean AUC0-∞ about 2" /><sentence text="6 and 3" /><sentence text="3 times higher, than after amenamevir alone" /><sentence text=" Amenamevir has the potential to be involved in CYP3A-mediated pharmacokinetic interactions in clinical practice"><entity charOffset="1-11" id="DDI-PubMed.30044899.s12.e0" text="Amenamevir" /></sentence><sentence text="" /></document>